Background and purpose
Neuromyelitis optica spectrum disorders (NMOSD) is an inflammatory demyelinating disorder with optic neuritis (ON) and/or longitudinally extensive transverse myelitis (LETM) episodes. We now know that NMOSD is associated with antibodies to aquaporin 4 (AQP4) which is highly concentrated on astrocytic end-feet at the blood-brain barrier. Immune-mediated disruption of blood brain barrier may manifest as contrast enhancement (CE) on brain MRI. We aim to delineate extent and frequency of CE on brain MRI within one month of ON and/or LETM attacks and to correlate CE with outcomes measures.
Methods
Brain MRIs of NMOSD patients were evaluated for patterns of CE (periependymal, cloud-like, leptomeningeal, etc.). Fisher’s exact test was used to evaluate differences between the proportions of CE in seropositives and seronegatives for aquaporin-4 antibodies. Mann-Whitney test was used to compare annualized relapse rate (ARR) and disease duration between patients with and without CE, and with and without seropositivity.
Results
Brain MRIs of 77 patients were evaluated; 59 (10 male, 49 female) were scanned within one month of ON and/or LETM attacks and were included in the analysis. Forty-eight patients were seropositive, 9 were negative and 2 were not tested. Having brain CE of any type during acute attack was significantly associated with higher ARRs (p=0.03) and marginally associated with shorter disease duration (p=0.05). Having periependymal CE was significantly associated with higher ARRs (p=0.03).
Conclusion
Brain MRIs of NMOSD patients with CE during an acute relapse of ON and/or LETM are associated with increased annual relapse rate.